Cas:900506-25-4 4-(Benzyloxy)-1H-indazole-3-carbaldehyde manufacturer & supplier

Chemical Name:4-(Benzyloxy)-1H-indazole-3-carbaldehyde

CAS.NO:900506-25-4

Synonyms:4-(Benzyloxy)-1H-indazole-3-carbaldehyde;4-Benzyloxyindazole-3-carboxaldehyde;1H-Indazole-3-carboxaldehyde, 4-(phenylmethoxy)-

Molecular Formula:C₁₅H₁₂N₂O₂

Molecular Weight:252.268

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:485.9±30.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.707

PSA:54.98000

Exact Mass:252.089874

LogP:2.61

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(Benzyloxy)-1H-indazole-3-carbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indazole-3-carboxaldehyde, 4-(phenylmethoxy)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Benzyloxyindazole-3-carboxaldehyde Use and application,1H-Indazole-3-carboxaldehyde, 4-(phenylmethoxy)- technical grade,usp/ep/jp grade.

Related News: The Department of Health and Human Services asked the Defense Department to provide several facilities capable of housing at least 250 people in individual rooms through to February 29, the Pentagon said. 4-(Benzyloxy)-1H-indazole-3-carbaldehyde manufacturer Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. 4-(Benzyloxy)-1H-indazole-3-carbaldehyde supplier The Department of Health and Human Services asked the Defense Department to provide several facilities capable of housing at least 250 people in individual rooms through to February 29, the Pentagon said. 4-(Benzyloxy)-1H-indazole-3-carbaldehyde vendor Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. 4-(Benzyloxy)-1H-indazole-3-carbaldehyde factory The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added.